Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2025-01-09 AGM Information
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团2025年第一次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as the "2025 First Extraordinary General Meeting (临时股东大会) Meeting Materials" of KPC Pharmaceuticals, Inc. It contains detailed agenda items, voting procedures, and explanations of proposals to be voted on by shareholders, including amendments to the company's articles of association, estimates of related party transactions, and board and supervisory committee elections. The content is typical of materials prepared and distributed for a shareholders' meeting to inform and guide shareholders on the meeting's proceedings and resolutions. There is no indication that this is a report of voting results or a brief announcement; rather, it is the full meeting materials. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting. Therefore, the document should be classified as AGM Information (AGM-R).
2025-01-09 Chinese
昆药集团关于参加全国中成药采购联盟集中采购拟中选的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the company's participation and tentative selection results in a national centralized procurement for traditional Chinese medicine products. It details the products selected, their specifications, prices, and the potential impact on the company's sales and market position. The document is dated January 3, 2025, and is structured as a formal public announcement with no financial statements or detailed financial analysis included. It does not contain quarterly or annual financial results, audit information, or management discussion and analysis. The document is relatively short (1966 characters) and serves as a notification of a business event (procurement selection results) rather than a financial report or regulatory filing. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other specific categories.
2025-01-02 Chinese
昆药集团关于2025年日常关联交易预估的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Kunming Pharmaceutical Corporation regarding the estimated daily related party transactions for the year 2025. It includes extensive financial data, descriptions of related parties, transaction amounts, pricing policies, and the impact on the company. The document is an official announcement about anticipated related party transactions, which is a type of capital or financing update related to the company's operational dealings with affiliates. It is not an annual report, audit report, earnings release, or management report. It is also not a simple announcement of a report publication but a substantive disclosure of related party transaction estimates and policies. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2024-12-25 Chinese
昆药集团十届三十次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the supervisory board (监事会) of Kunming Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, and the approval of a proposal regarding estimated related party transactions for 2025. It is a formal announcement of a board meeting decision rather than a full report or financial statement. There is no indication of financial data, audit results, or regulatory filings beyond the board resolution. This fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2024-12-25 Chinese
昆药集团股份有限公司董事会战略与ESG委员会实施细则(2024年12月修订）
Governance Information Classification · 95% confidence The document is titled as the 'Board of Directors Strategy and ESG Committee Implementation Rules' for Kunming Pharmaceutical Group Co., Ltd., revised in December 2024. It details the committee's composition, responsibilities, decision-making procedures, and meeting rules related to strategic planning and ESG (Environmental, Social, and Governance) management. There are no financial statements, earnings data, or regulatory filings such as annual or interim reports. The document is a governance-related internal rules document describing board committee structure and functions, which fits the Governance Information (CGR) category. The document length is 2686 characters, which is consistent with a detailed governance policy rather than a brief announcement or a full financial report.
2024-12-25 Chinese
昆药集团十届三十八次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Kunming Pharmaceutical Group Co., Ltd. It details voting results on various company governance matters such as related party transactions, amendments to internal management rules, and the scheduling of a shareholders' meeting. The document is short (1037 characters) and primarily reports on board decisions and voting outcomes rather than providing detailed financial data or full reports. It does not contain financial statements or comprehensive management discussion. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2024-12-25 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.